TSXV:CLAS.H - Post by User
Post by
AngelaLon Jan 01, 2022 1:17pm
293 Views
Post# 34276179
Exciting next steps
Exciting next steps 2022 will be fascinating to watch Claritas. When the company enters its Phase 1 trial with R-107, ideally very soon, and readies for a Phase 2 pulmonary hypertension trial it will cross over from being a preclinical enterprise with a lot of hope to a clinical-stage biotech with a unique platform technology. That should get them institutional funding and potential strategic collaborations. Companies with those attributes and at that stage of development are typically traded on the NASDAQ at a $40-100M market cap. The TSXV is not in the same league as the NAADAQ but the company could uplist.